Drug Profile

Pembrolizumab biosimilar - Celltrion

Alternative Names: CT P51

Latest Information Update: 30 Apr 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Celltrion
Class Antineoplastics; Antivirals; Immunotherapies; Monoclonal antibodies; Tumour-agnostic therapies
Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

30 Jan 2025 Phase-III clinical trials in Non-small cell lung cancer (Combination therapy, First-line therapy, Metastatic disease, Late-stage disease) in Georgia (Parenteral) (NCT06939595)
30 Dec 2024 Celltrion plans a phase III trial for Non-squamous non-small cell lung cancer (Metastatic disease, First line therapy) (Parenteral) (EUCT2024-514048-98-00) (Celltrion pipeline, December 2024)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com